One Versus Two Versus Three Daily Rapid-Acting Insulin Injections of APIDRA (Insulin Glulisine) as Add-on to Lantus and Oral Sensitizer Basal Therapy in Type 2 Diabetes: a Multicenter, Randomized, Parallel, Open-Label Clinical Study

Trial Profile

One Versus Two Versus Three Daily Rapid-Acting Insulin Injections of APIDRA (Insulin Glulisine) as Add-on to Lantus and Oral Sensitizer Basal Therapy in Type 2 Diabetes: a Multicenter, Randomized, Parallel, Open-Label Clinical Study

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2009

At a glance

  • Drugs Insulin glulisine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Jun 2009 Results were reported at the 2009 ADA.
    • 06 Jun 2009 Results were presented at the American Diabetes Association annual meeting, according to a sanofi-aventis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top